-
81.
公开(公告)号:WO2021053058A1
公开(公告)日:2021-03-25
申请号:PCT/EP2020/075948
申请日:2020-09-17
Applicant: MEREO BIOPHARMA 4 LIMITED , DUKE UNIVERSITY , NATIONAL CANCER INSTITUTE
Inventor: PARKIN, Jacqueline , SUNG, Anthony , PAVLETIC, Steven. Z , IM, Annie , HOLTZMAN, Noa. G
Abstract: The invention relates to treatments for organ rejection, in particular to treatments for lung transplant associated bronchiolitis obliterans syndrome by administering a neutrophil elastase inhibitor, such as alvelestat. The invention also relates to treatments for graft versus host disease.
-
公开(公告)号:WO2020201458A1
公开(公告)日:2020-10-08
申请号:PCT/EP2020/059460
申请日:2020-04-02
Applicant: 4D PHARMA CORK LIMITED
Inventor: O'TOOLE, Paul , SHANAHAN, Fergus , JEFFERY, Ian , O'HERLIHY, Eileen , DAS, Anubhav
Abstract: The application provides new and improved methods for diagnosing BAM.
-
公开(公告)号:WO2020201457A1
公开(公告)日:2020-10-08
申请号:PCT/EP2020/059459
申请日:2020-04-02
Applicant: 4D PHARMA CORK LIMITED
Inventor: O'TOOLE, Paul , SHANAHAN, Fergus , JEFFERY, Ian , O'HERLIHY, Eileen , DAS, Anubhav
Abstract: The application provides new and improved methods for diagnosing IBS.
-
公开(公告)号:WO2019215345A1
公开(公告)日:2019-11-14
申请号:PCT/EP2019/062236
申请日:2019-05-13
Applicant: 4D PHARMA RESEARCH LIMITED
Inventor: MULDER, Imke Elisabeth , AHMED, Suaad , ETTORRE, Anna , REID, Sarah Anne , DINAN, Ted , CRYAN, John
IPC: A61K35/74 , A23L33/135 , A61P1/00 , A61P11/06 , A61P3/10 , A61P17/06 , A61P19/02 , A61P37/00 , A61P35/00 , A61P43/00
Abstract: The invention provides a composition comprising a bacterial strain of the genus Megasphaera , for use in the treatment or prevention of an autoimmune or inflammatory disorder or cancer
-
公开(公告)号:WO2019141999A8
公开(公告)日:2019-07-25
申请号:PCT/GB2019/050144
申请日:2019-01-18
Applicant: 4D PHARMA RESEARCH LIMITED
Inventor: STEVENSON, Alexander
IPC: A61K35/74 , A61K39/395 , A61P35/00
Abstract: The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.
-
公开(公告)号:WO2016180784A1
公开(公告)日:2016-11-17
申请号:PCT/EP2016/060344
申请日:2016-05-09
Applicant: PROQR THERAPEUTICS II B.V.
Inventor: KLEIN, Bart
CPC classification number: A61K31/60 , A61K31/7125 , A61K45/06 , A61K2300/00
Abstract: Potential side effects of unintentional activation of platelets by phosphorothioated oligonucleotides are minimised in various ways, including a combination therapy, wherein PS-ONs are combined, in one composition, a kit-of-parts, and/or in a combination therapy regime, with either or both specific platelet activation pathway inhibitors, and/or the common platelet aggregation pathway.
Abstract translation: 通过硫代磷酸化寡核苷酸无意激活血小板的潜在副作用以各种方式被最小化,包括联合疗法,其中PS-ON组合在一个组合物中,一组试剂盒和/或组合疗法方案中,与 特异性血小板激活途径抑制剂,和/或普通血小板聚集途径中的一种或两种。
-
公开(公告)号:WO2016135334A1
公开(公告)日:2016-09-01
申请号:PCT/EP2016/054164
申请日:2016-02-26
Applicant: PROQR THERAPEUTICS II B.V.
Inventor: BIASUTTO, Patricia Coromoto , CHAN, Hee, Lam
IPC: C12N15/113 , A61K31/712 , A61K31/7125
CPC classification number: C12N15/113 , A61K31/7125 , C12N2310/11 , C12N2310/315 , C12N2310/346 , C12N2320/33 , C12N2330/51 , C12N2310/321 , C12N2310/3521
Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
Abstract translation: 反义寡核苷酸靶向CEP290基因的内含子26中的突变并减少异常外显子包含在CEP290 mRNA中。 寡核苷酸包括不超过3个连续的鸟苷,具有不超过60%的鸟苷核碱基,包括至多一个CpG序列,和/或不具有形成包含3个或更多个连续互补碱基对的发夹的潜力。
-
公开(公告)号:WO2016135154A1
公开(公告)日:2016-09-01
申请号:PCT/EP2016/053792
申请日:2016-02-23
Applicant: NOVARTIS AG , NORTHEASTERN UNIVERSITY
Inventor: BRITO, Luis , O'HAGAN, Derek , MANSOOR, Amiji , SHAH, Ruchi Rudraprasad , SINGH, Manmohan
CPC classification number: A61K9/1075 , A61K9/0019 , A61K39/39 , A61K47/06 , A61K47/26 , A61K2039/55566
Abstract: Oil-in-water emulsions with small droplet sizes can be formed without requiring either microfluidisation or heating to cause phase inversion, but rather by simple mixing of a pre-mixed composition of oil and surfactant with aqueous material. The oil/surfactant compositions can be mixed with an excess volume of aqueous material to spontaneously form an oil-in-water emulsion with droplets having a diameter
Abstract translation: 可以形成具有小液滴尺寸的水包油乳液,而不需要微流化或加热以引起相转化,而是通过将油和表面活性剂的预混合组合物与水性材料简单混合。 油/表面活性剂组合物可以与过量体积的水性材料混合以自发形成具有直径<250nm的液滴的水包油乳液,其显示出良好的佐剂活性。 通常,油占油/表面活性剂组合物的体积的50体积%,表面活性剂占剩余部分。
-
公开(公告)号:WO2016124909A1
公开(公告)日:2016-08-11
申请号:PCT/GB2016/050235
申请日:2016-02-02
Applicant: ATLAS GENETICS LIMITED
Inventor: EDWARDS, Tom
CPC classification number: B01L3/502738 , B01L3/502707 , B01L3/502715 , B01L3/523 , B01L3/527 , B01L2200/0689 , B01L2200/12 , B01L2300/044 , B01L2300/0887 , B01L2400/0683 , B32B3/266 , B32B3/30 , B32B5/142 , B32B7/045 , B32B7/12 , B32B15/08 , B32B15/20 , B32B27/08 , B32B27/32 , B32B27/36 , B32B2255/06 , B32B2255/10 , B32B2255/26 , B32B2307/31 , B32B2307/50 , B32B2307/582 , B32B2307/7246 , B32B2439/80 , B65B3/003 , B65B9/042 , B65B39/007 , B65B39/12 , B65B47/00 , B65B47/04 , B65D75/367
Abstract: A blister assembly comprises at least one collapsible blister adapted, as it is collapsed, to eject a liquid contained therein. The blister assembly comprises a first layer (130) having at least one blister chamber (150) and a second layer (131) sealed to the first layer at least around a periphery of the at least one blister chamber such that a liquid is contained between the first layer and the second layer. The seal between the first and second layers comprises a first planar portion having a first peel strength and a second planar portion having a second peel strength, wherein the first peel strength is greater than the second peel strength, such that when pressure is applied to the blister, the second portion of the seal breaks to release the liquid contained within the chamber into the liquid inlet. The blister assembly further comprises at least one discontinuity (142) formed in the first and second layers in the region of the first portion of the seal, such that a shear force is required to delaminate the first and second layers in that region.
Abstract translation: 泡罩组件包括至少一个可折叠的泡罩,其可折叠地适于喷射其中容纳的液体。 泡罩组件包括具有至少一个泡罩室(150)的第一层(130)和至少围绕至少一个泡罩室的周边密封到第一层的第二层(131),使得液体包含在 第一层和第二层。 第一和第二层之间的密封包括具有第一剥离强度的第一平面部分和具有第二剥离强度的第二平面部分,其中第一剥离强度大于第二剥离强度,使得当将压力施加到 水泡,密封件的第二部分断开,将容纳在室内的液体释放到液体入口中。 泡罩组件还包括形成在密封件的第一部分区域中的第一和第二层中的至少一个不连续部分(142),使得需要剪切力来分层该区域中的第一和第二层。
-
公开(公告)号:WO2015158927A1
公开(公告)日:2015-10-22
申请号:PCT/EP2015/058533
申请日:2015-04-20
Applicant: NOVARTIS AG
Inventor: HO, Samuel , PARKER, David , FEKKES, Peter , DE SOUZA, Ivna , MASON, Peter , SUPHAPHIPHAT, Pirada
IPC: A61K39/12 , A61K39/145
CPC classification number: C07K14/005 , A61K39/00 , A61K39/12 , A61K2039/575 , C12N7/00 , C12N2760/16111 , C12N2760/16134 , C12N2760/16143 , C12N2760/16151 , C12N2760/16234 , C12N2760/16243 , C12N2760/16251
Abstract: Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.
Abstract translation: 本文公开了提高蛋白质产量和细胞生产率的方法。 化学试剂促进生物分子的宿主细胞生成以提高产物产率。
-
-
-
-
-
-
-
-
-